Joris Kleintjens

Diegem, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Budget impact analysis of skytrofa for the treatment of pediatric growth hormone deficiency in a US health plan.

Budget impact analysis of skytrofa for the treatment of pediatric growth hormone deficiency in a US health plan.

Journal: Journal of medical economics

Published: September 13, 2025

Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case Study.

Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case Study.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 04, 2024

A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France.

A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France.

Journal: PloS one

Published: May 26, 2020

Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix™.

Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix™.

Journal: Epidemiology and infection

Published: July 05, 2016

Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.

Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.

Journal: Drugs in R&D

Published: September 30, 2015

Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.

Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.

Journal: PharmacoEconomics

Published: January 12, 2015

How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines?

How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines?

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

National Immunisation Technical Advisory Groups - A Framework For Assessment and Insights From Research.

National Immunisation Technical Advisory Groups - A Framework For Assessment and Insights From Research.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilisation Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy.

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilisation Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.

Journal: PharmacoEconomics

Published: September 14, 2013

Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.

Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.

Journal: Applied health economics and health policy

Published: May 08, 2013

Personalized approach to growth hormone treatment: clinical use of growth prediction models.

Personalized approach to growth hormone treatment: clinical use of growth prediction models.

Journal: Hormone research in paediatrics

Published: December 20, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026